About this trial
The goal of this clinical trial is to learn if adding standardized manual thrombus aspiration to primary percutaneous coronary intervention (PPCI) works better to improve heart health outcomes and protect long-term heart function in adults with acute ST-segment elevation myocardial infarction (STEMI) and a high blood clot burden in the heart's arteries. The main questions it aims to answer are:
* Does PPCI plus manual thrombus aspiration lower the risk of serious heart problems one year after treatment, compared to PPCI alone? * Can manual thrombus aspiration better protect long-term heart function in people with a high blood clot burden? Researchers will compare two groups of participants-one group getting PPCI plus manual thrombus aspiration and one group getting only PPCI-to see if the aspiration treatment leads to fewer serious heart problems, better long-term heart function, and similar safety (including no higher risk of stroke).
Participants will:
* Have a heart artery scan (coronary angiography) to confirm a high blood clot burden * Be randomly assigned to one of the two treatment groups for their PPCI procedure * Complete follow-up checks at 30 days, 6 months, and 1 year after treatment, including heart function tests (like echocardiograms) * Have heart magnetic resonance (CMR) scans if selected, to measure heart tissue damage and heart function * Have their heart health status and any adverse events recorded throughout the study
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged ≥18 years old, diagnosed with acute ST-segment elevation myocardial infarction (STEMI) (chest pain plus ST-segment elevation ≥1mm or new-onset left bundle branch block [LBBB]) with symptom onset < 12 hours.
Planned to undergo primary percutaneous coronary intervention (PPCI).
High thrombus burden in the target vessel (TIMI thrombus grade ≥3, or visible floating thrombus) confirmed by coronary angiography.
Reference diameter of the target vessel ≥2.75mm, with the lesion suitable for the passage of an aspiration catheter.
Disqualifiers
Cardiogenic shock (Killip class IV) or requiring mechanical circulatory support.
A history of previous coronary artery bypass grafting (CABG).
Concurrent intervention required for non-culprit vessels.
Severe bleeding tendency (e.g., INR > 2.5, platelet count < 50×10⁹/L).
Trial design
Parallel
Treatments tested in this trial
Manual Thrombus Aspiration
Procedure/SurgeryManual thrombus aspiration is an adjunct to primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI) patients with angiographically confirmed high thrombus burden (TIMI thrombus grade ≥3 or floating thrombus). Performed before stent implantation on the infarct-related vessel, the procedure uses a study-designated modern 6Fr-compatible manual aspiration catheter, with a 50ml large-volume locked syringe for stable negative pressure and heparinized normal saline for catheter flushing. Under fluoroscopy, the catheter is advanced 1-2cm distal to the thrombus, then retracted at a uniform speed of 1cm/sec with continuous negative pressure. Aspiration can be repeated up to 3 times if needed; successful aspiration is confirmed by visible thrombotic material and improved angiographic findings. No bailout aspiration is performed for failed cases, which proceed directly to routine balloon dilation and stent implantation.
Primary Percutaneous Coronary Intervention (PPCI)
Procedure/SurgeryStandard primary percutaneous coronary intervention with balloon dilation and stent implantation for STEMI
Treatment groups
Trial outcomes
Primary outcomes
Composite major adverse cardiovascular events (MACEs) at 1 year after the procedure
The primary outcome is the cumulative incidence of composite MACEs, including four components: cardiovascular death, recurrent myocardial infarction, target vessel revascularization (TVR), and rehospitalization for heart failure.
Secondary outcomes
Composite MACEs at 180 days after the procedure
Cumulative incidence of composite MACEs, including cardiovascular death, recurrent myocardial infarction, target vessel revascularization (TVR), and rehospitalization for heart failure.
Composite major adverse cardiovascular and cerebrovascular events (MACCEs) at 30 days after the procedure
Incidence of MACCEs, including cardiovascular death, recurrent myocardial infarction, target vessel revascularization (TVR), rehospitalization for heart failure, and ischemic stroke.
Immediate TIMI flow grade after PCI
Proportion of patients with TIMI flow grade 3 vs. \< 3 in the infarct-related artery immediately after percutaneous coronary intervention (PCI).
Immediate ST-segment resolution (STR) rate after PCI
Proportion of patients with ST-segment resolution ≥ 70% immediately after percutaneous coronary intervention (PCI).
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: